WELICEF-S 1.5 is a higher-strength Ceftriaxone-Sulbactam injectable antibiotic positioned for selected serious bacterial infections requiring parenteral therapy. Its dual-action approach provides established cephalosporin antibacterial activity alongside beta-lactamase inhibition, making it particularly relevant to hospital and institutional settings. The high-strength presentation adds depth to a PCD Pharma Injectable Antibiotic portfolio and supports physician-focused anti-infective positioning.
Selected moderate to severe susceptible bacterial infections.
Sulbactam provides beta-lactamase inhibition that can preserve Ceftriaxone activity.
No, it should be reserved for clinically appropriate bacterial indications.
Administration should occur under professional supervision with careful review of allergy history, infection severity and patient-specific risk factors. Culture and susceptibility testing should guide therapy whenever possible. Monitor response and safety parameters during treatment, particularly in prolonged or complicated infections.
Adverse effects may include diarrhea, nausea, vomiting, abdominal discomfort, headache, rash and injection-site reactions. Hypersensitivity reactions can occur, particularly in beta-lactam-allergic patients. Liver-related laboratory abnormalities or other treatment-related changes may occur. Severe allergic reactions, persistent or severe diarrhea, significant rash or other unexpected symptoms require prompt medical attention and possible treatment modification.
WELICEF-S 1.5: Ceftriaxone binds to bacterial penicillin-binding proteins and blocks cell-wall synthesis, producing bactericidal activity. Sulbactam inhibits susceptible beta-lactamases and helps protect Ceftriaxone against enzymatic hydrolysis. Together, the agents provide complementary antibacterial mechanisms and may improve activity against selected beta-lactamase-producing organisms. The formulation is intended for infections where broad-spectrum injectable therapy is clinically appropriate and justified.
